Nab-Paclitaxel With Local Therapy for Relapsed Small Cell Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a chemotherapy drug (nab-paclitaxel) combined with local treatments like radiation for small cell lung cancer that has come back after previous treatment. The goal is to see if this combination helps patients live longer and control their cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that has spread to other parts of your body (extensive-stage) and has gotten worse despite at least one prior treatment
- You must be between 18 and 75 years old and in good enough health to tolerate treatment (ECOG score 0–1)
- You must have measurable cancer visible on imaging scans
- Your blood counts, liver, and kidney function must be adequate based on recent lab tests
- You cannot have untreated or active cancer in your brain or spinal cord (though treated, stable brain tumors may be allowed)
- You must provide a tumor tissue sample during the study for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This study tests a combination of an oral targeted therapy (anlotinib) with a liposomal form of chemotherapy and an immunotherapy drug as maintenance treatment for extensive-stage small cell lung cancer after initial treatment. It aims to keep the cancer from growing again.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.